Pfizer Corporation

Zoetis Services LLC

Zoetis LLC

Ah USA 42 LLC

Nathan Anthony Logan Chubb

Denis Billen

Bernard Joseph Banks

Lee Richard Roberts

David Morris Gethin

Kim Thomas Hall

Nigel Derek Arthur Walshe

Richard Andrew Ewin

Christelle Lauret

Mark Roger Cox

Jerome Sebastien Dauvergne

Valerie Ann Vaillancourt

James John Eshelby

Darren John Schulz

Michael P Curtis

Sanjay Menon

Graham M Kyne

Susan M K Sheehan

Donald James Skalitzky

Michael Stephen Pacey

Timothy Lee Stuk

Patrick F M Meeus

John Adam Wendt

Tom L McTier

Kevin Evans

William Howson

Sean David William Greenwood

The present invention relates to a novel antiparasitic composition comprising an effective amount of a) a Formula (1) compound, wherein R, R, R, R, R, R, and n are as defined herein, stereoisomer thereof, or a pharmaceutical or veterinary acceptable salt thereof, b) a macrocyclic lactone or derivative thereof and c) optionally, at least one additional veterinary agent, and further comprising at least one veterinary or pharmaceutical acceptable carrier; and a method of treating an animal with a parasitic infection, by administering an effective amount of said composition to the animal in need thereof. 

Spirocyclic isoxazoline parasiticidal combinations

This invention recites dihydrofuran substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. The substituents A, R, R, R, R, R, R, R, and n are as described herein. 

Dihydrofuran azetidine derivatives as antiparasitic agents

The invention recites spirocyclic isoxazoline derivatives of Formula (V.1), Formula (V.2), Formula (V.1.1), and Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, processes for making, and their use as a parasiticide in an animal. The variables A, V, Z, W, W, W, W, Y, X, R, R, R, R, R, R, n, and '' are as described herein.

Spirocyclic isoxazoline derivatives as antiparasitic agents

This invention recites isoxazoline substituted azetidine derivatives of Formula (1) stereoisomers thereof, veterinarily acceptable salts thereof, compositions thereof, and their use as a parasiticide in mammals and birds. R, R, R, R, R, R, R, and n are as described herein.

Isoxazoline derivatives as antiparasitic agents

This invention relates to a combination product comprising a compound of formula I wherein X, R, R, R, R, R, R, Rand Rare as described herein, and one or more further biologically active compounds as described herein, particularly anti-parasitic agents.

Substituted arylpyrazoles

This invention relates to a combination product comprising a range of 1-aryl-4 -cyclopropylpyrazoles in which there is at least one fluorine attached to the cyclopropyl ring, and one o more further therapeutic agents, particularly anti-parasitic agents.

This invention relates to a range of alpha substituted 2-benzyl substituted imidazole compounds and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.

Substituted imidazoles

This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles in which there is at least one fluorine attached to the cyclopropyl ring, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.

Compounds of formulae (IA) and (IB):wherein R, R, R, Arand X are as defined above, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension.

Pyrazole compositions

Nitrogen-containing heterocycles having parasiticidal properties

Growing community of inventors

Sandwich, United Kingdom

Nathan Anthony Logan Chubb